Kalaris reports Q2 2026 results, dosing continues in TH103 mid-stage trial

Kalaris Therapeutics reported financial results for the quarter ended June 30, 2026 on August 11, 2026, along with business updates on its lead program TH103, an investigational treatment for neovascular Age-related Macular Degeneration. The company said it is currently dosing patients in its Phase 1b/2 study of TH103 for neovascular Age-related Macular Degeneration.¹

The Phase 1b/2 trial is a multi-ascending dose, dose-finding study evaluating up to four monthly loading doses of TH103¹, designed to assess the safety and efficacy of repeat doses of TH103 at different dose levels and to identify the optimal dose and regimen for potential Phase 3 development.¹ Preliminary data from this study is expected in the first half of 2027.¹ The company said it remains on track to begin potential Phase 3 trials by year-end 2027.

Kalaris also disclosed that expanded Phase 1a patient cohort data reinforced earlier BCVA, OCT, pharmacokinetic and time-to-retreatment findings from the original patient cohorts.¹ Separately, the company said it completed a new manufacturing batch that incorporated process enhancements further lowering already low levels of process impurities.¹

On the leadership side, Kalaris confirmed the previously announced hiring of Liisa Bayko as Chief Financial Officer and the appointment of Laurie Keating to its Board of Directors.¹

Financially, Kalaris had cash, cash equivalents and marketable securities of $93.5 million as of June 30, 2026, down from $118.0 million at the end of 2025.¹ The company said this balance is expected to fund operations into the fourth quarter of 2027.¹ Net loss for the quarter was $11.5 million, compared with $11.4 million in the same quarter of 2025.¹